Search research articles
Contact Us
Filters
Showing results (31-40 of 54) with videos related to
Page
of 6
Sort By:
British Journal of Cancer
|
March 5, 2009
Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy
V Catalano, F Loupakis, F Graziano, et al.
British Journal of Cancer
|
August 30, 2008
Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy
F Graziano, A Ruzzo, F Loupakis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 14, 2013
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)
L Fornaro, S Lonardi, G Masi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials
M D Berger, S Stintzing, V Heinemann, et al.
The Pharmacogenomics Journal
|
October 8, 2014
Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancer
L Benhaim, W Zhang, T Wakatsuki, et al.
The Pharmacogenomics Journal
|
March 2, 2016
Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer
F Graziano, A Ruzzo, E Giacomini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer
M Suenaga, M Schirripa, S Cao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 21, 2015
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial
G Masi, L Salvatore, L Boni, et al.
The Pharmacogenomics Journal
|
March 23, 2016
Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab
F S Falvella, C Cremolini, R Miceli, et al.
ESMO Open
|
June 2, 2022
Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC
S Kopetz, A Grothey, E Van Cutsem, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 54) with videos related to
Sort By:
Page
of 6
British Journal of Cancer
|
March 5, 2009
Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy
V Catalano, F Loupakis, F Graziano, et al.
British Journal of Cancer
|
August 30, 2008
Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy
F Graziano, A Ruzzo, F Loupakis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 14, 2013
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)
L Fornaro, S Lonardi, G Masi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials
M D Berger, S Stintzing, V Heinemann, et al.
The Pharmacogenomics Journal
|
October 8, 2014
Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancer
L Benhaim, W Zhang, T Wakatsuki, et al.
The Pharmacogenomics Journal
|
March 2, 2016
Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer
F Graziano, A Ruzzo, E Giacomini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer
M Suenaga, M Schirripa, S Cao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 21, 2015
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial
G Masi, L Salvatore, L Boni, et al.
The Pharmacogenomics Journal
|
March 23, 2016
Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab
F S Falvella, C Cremolini, R Miceli, et al.
ESMO Open
|
June 2, 2022
Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC
S Kopetz, A Grothey, E Van Cutsem, et al.
Page
of 6